Immunosenescence (the aging immune system)
The immune system ages on its own schedule, and badly: the thymus that trains new immune cells is mostly fat by midlife, the surveillance cells that hunt cancers and infections lose their edge, and the repertoire fills with worn-out cells. The best-evidenced countermeasure is vaccines designed for older immune systems; exercise is the most plausible lifestyle lever, while the molecular shortcuts in the headlines remain unproven.
Immunosenescence is the age-related remodelling and decline of the immune system, and although it is not one of the twelve hallmarks of aging, it sits alongside their integrative tier — it is less a single root cause than a system-wide failure that both results from upstream damage and then accelerates it.[1] Much of its story can be told through one cytokine — interleukin-15 (IL-15) — which turns out to be a central regulator of the immune cells that age worst, and a useful lens on why the body's defences fade and what, realistically, keeps them sharp.
How confident should you be
The decline itself — Strong. Vaccines designed for older adults — Strong, from randomised trials. IL-15 as the organising mechanism — Moderate, and largely from cell and animal work. Exercise as an immune-aging lever — Weak. The centenarian finding — observational. Drugs and supplements — Weak, with a real Caution attached.
Two things on this page are solid: the immune system measurably deteriorates with age, and that deterioration feeds the same inflammation that drives age-related disease. The interpretive frame — that one cytokine, interleukin-15, ties it together — is a useful lens rather than a settled fact, and most of the evidence behind it is in cultured cells, mice and rats. The centenarian data is a snapshot of people who already aged well, not a demonstration that anything caused it. And the pharmacology section is about cancer drugs, evaluated in seriously ill patients under close monitoring — a setting that tells you very little about what they would do to a healthy person.
One note on the numbers below. Where a result is followed by a range in parentheses — a 95% confidence interval — that range is where the true effect most plausibly lies; when it spans zero, the result is compatible with no effect at all.
What breaks down
Strong for the description; the functional consequences are cohort-level associations.
The most consequential single event is thymic involution. The thymus — the organ that schools fresh T-cells — keeps roughly the same overall size through life, but its working tissue starts dwindling from the first year of life, and from the teenage years on fat steadily fills the space around it while the working tissue keeps dwindling for the rest of life.[2] Its output of new naive T-cells falls but does not stop: measurable output continues well into late adulthood,[3] and a 2026 chest-scan study of more than 27,000 adults found that how much healthy thymus remains declines with age but varies widely from person to person.[4] As fewer new cells arrive, the immune system leans more on its existing memory cells and is slower to recognise threats it hasn't seen before — which is part of why vaccines work less well and new infections hit harder with age.[5]
Two recent observational lines suggest the adult thymus still matters for hard outcomes. Adults who had the thymus removed during heart or chest surgery had more deaths and cancers over the next five years than similar surgical patients who kept it — about 8% versus 3% died.[6] In the chest-scan study, older heavy smokers whose thymus looked healthier were about half as likely to die over 12 years, with less lung cancer and fewer deaths from heart and blood-vessel disease; in a smaller general-population cohort only the heart and blood-vessel link held up after adjustment. A healthier-looking thymus also went with not smoking, less obesity and more physical activity.[7] Neither shows that anything you do to the thymus changes outcomes.
At the same time the surviving T-cells wear out in a characteristic way. Late-stage T-cells pick up the surface markers of senescence, such as CD57, and divide poorly when they meet their target; rather than falling idle, many switch to a cruder, natural-killer-like style of killing. IL-15 itself helps these worn-out cells expand — an early glimpse of the too-much-IL-15 problem described below.[8] Meanwhile the innate side weakens too. Natural killer (NK) cells — the body's first responders against virus-infected and pre-cancerous cells — each kill less well with age, even though the number of NK cells often holds steady or rises.[9] In a Japanese community cohort of adults mostly over 40, people with low NK activity developed more cancer over 11 years,[10] and in nursing-home residents with poor physical function, low NK activity went with more infections and more deaths from infection.[11] Both are single observational studies. The net effect is a system that is simultaneously less protective and more inflammatory — the immune contribution to inflammaging, the chronic, low-grade, germ-free inflammation of older bodies covered under chronic inflammation.
IL-15: the cytokine that ties immune aging together
Moderate. The receptor biology is well established; the framing of IL-15 as the organising thread is an interpretation, and the anti-senescence effects below are in cells and mice.
If one molecule sits at the centre of immune aging, it is IL-15. It is the principal survival and growth signal for exactly the cells that fare worst with age — memory CD8⁺ T-cells and NK cells.[12]
What makes IL-15 unusual is how it is delivered. Rather than being released freely into the blood — which would be dangerous for so potent an inflammatory signal — it is mostly handed over cell-to-cell: a producing cell holds IL-15 on its surface and presents it directly to a neighbouring lymphocyte, a mechanism called trans-presentation that keeps the signal local and tightly controlled.[13] When that signal lands, it switches on a growth-signalling cascade and raises an anti-death protein, which together are what keep memory T-cells and NK cells alive.[14]
IL-15 also pushes directly against T-cell aging. It sustains the activity of telomerase, the enzyme that maintains the protective caps on chromosomes whose erosion is covered under telomere attrition; in laboratory memory CD8⁺ T-cells, IL-15 minimises telomere loss across repeated divisions and helps preserve their replicative lifespan.[15] In human tumour-specific memory T-cells grown with IL-15 rather than the related signal IL-2, the cell-cycle brakes that enforce senescence (p16, p21, p53) were turned down and senescence was delayed, and those cells held back tumour growth better after transfer into immune-deficient mice.[16] The catch — and it is the central catch of the whole topic — is that these are effects of appropriate IL-15 signalling. Too much, for too long, does the opposite, as the section below on the pulsatile principle explains.
NK cells and the clearing of senescent cells
Moderate as mechanism; the evasion tactics are cell and animal work.
One of the most important jobs of a youthful immune system is senolysis — physically finding and killing senescent cells before they accumulate. In mice, disabling the killing machinery of NK cells and cytotoxic T-cells lets senescent cells pile up, drives chronic inflammation and shortens life, so these cells are thought to be the main clean-up crew.[17] IL-15 keeps those cells alive and armed, so it probably supports this clean-up too — but no study has yet shown that directly, and none in people. When NK function fades with age, senescent cells linger and their inflammatory secretions spread — the immune-surveillance failure that the cellular senescence article describes from the senescent cell's side.
Senescent cells do not go quietly. They actively evade immune clearance using tactics that look strikingly like a tumour's. They secrete an immunosuppressive signal that blunts the receptors NK cells use to recognise a target, and they shed soluble decoy versions of the very molecule those receptors look for, mopping up and exhausting them before the NK cell can make contact — effectively cloaking themselves.[18] This is part of why simply "boosting" immunity is harder than it sounds: the targets fight back.
The centenarian paradox
Observational. A snapshot of people who already aged well — it cannot tell you what caused it.
A suggestive natural experiment comes from people who have aged exceptionally well. In a cross-sectional study of 30 people aged over 95 — most of them women — circulating IL-15 was higher than in either adults under 60 or people aged 60 to 89.[19] Thirty people, measured once, two decades ago: suggestive, not settled. A 2024 study in Kazakhstan of 40 people aged 90 and over, all still fairly healthy and independent, also found higher blood IL-15 than in 50 adults aged 46 to 60, though several other inflammatory signals were raised too, and it is another small one-time snapshot.[20] The finding stands out because ordinary aging seems to go the other way. Pooling 59 studies of healthy adults, people over 65 typically have lower blood IL-15 than younger adults, except overweight older adults, whose levels are higher, so body fat muddies the picture.[21] On its face, high IL-15 in the very old is a paradox: IL-15 is pro-inflammatory, so high levels ought to mean runaway inflammaging. And in a separate cohort, the T-cells of high-performing centenarians proliferated more on stimulation, and carried longer telomeres and more telomerase activity, than those of both low-performing centenarians and 67-to-83-year-old controls. The distinction matters — low-performing centenarians looked like the controls, so this is a property of aging well, not of reaching 100.[22]
The usual explanation is that they run the opposing brake harder at the same time — but the evidence for that is thinner and more specific than it sounds. In a Chinese study that measured blood from 218 centenarians (with detailed T-cell tests on just 8 people per group), centenarians did not carry more of the regulatory T-cells that restrain inflammation than younger adults, and their naive T-cells were if anything worse at becoming them. What differed was the balance: compared with ordinary older adults, the ratio of inflammatory helper T-cells to regulatory T-cells had tipped back toward the regulatory side, and blood levels of IL-10, an anti-inflammatory signal, were higher; from lab tests on cells from 8 people per group, the authors inferred that each centenarian regulatory cell released more of it.[23] An Italian survey of 62 blood signalling molecules in 22 centenarians found no general rise in anti-inflammatory cytokines compared with middle-aged controls.[24] So neither study found more regulatory T-cells, the two disagree on the brake signals themselves, and both are small snapshots. The lesson the inflammaging article draws still fits, as a hypothesis: exceptional immune aging looks less like suppressing the immune system than like pairing active surveillance with well-tuned restraint.
The pulsatile principle, and where exercise fits
Moderate. The exhaustion result is in cultured human cells and mice; the exercise half rests on two human meta-analyses that disagree on how consistent the spike is.
The single most useful idea in this area is that IL-15 has to come in pulses. Brief, transient spikes rejuvenate immune cells; chronic, unremitting elevation exhausts them. When human NK cells are bathed continuously in IL-15, they initially ramp up but then suffer a metabolic collapse — fatty-acid oxidation falls, spare respiratory capacity disappears, and the cells lose their ability to kill.[25] Overdriving the cell's main growth-and-nutrient pathway is the culprit: dialling the signal back down, or simply giving the cells a break between exposures, prevents the exhaustion.[26] This is why continuous IL-15 drug dosing is the worry: exhausted cells also controlled tumours poorly once transferred into mice.[27] Whether the IL-15 elevations reported in obesity or persistent infection do the same thing in people has not been tested.
The body's natural way of generating those spikes is muscular work. Skeletal muscle is an endocrine organ, and during contraction it releases IL-15 as a myokine under the control of the cellular energy sensor AMPK; mice engineered to lack AMPK in muscle made less IL-15 and by 18 months had thinner skin with less collagen. Separately, in ordinary 23-month-old mice, daily low-dose IL-15 injections for 33 days partly reversed age-related skin thinning and collagen loss, as exercise did. The same study's human comparison found that active people aged 65 to 86 had less thinning of the outer skin layer than sedentary peers, though exercise did not protect against collagen loss in the deeper skin.[28] In humans, a meta-analysis of 15 studies in 411 people found that a single exercise session raises circulating IL-15 for a short time — a large effect on average (standardised mean difference 0.90, 95% CI 0.47–1.32), seen with both endurance and strength work at the moderate intensities studied. Across 12 studies in 899 people, chronic training left resting IL-15 essentially unmoved (0.40, 95% CI −0.08 to 0.88 — a range that includes no effect).[29] A larger 2024 analysis of healthy adults was less clear-cut: the average rise was similar in size but not statistically clear (0.95, 95% CI −0.23 to 2.13), with signs that small positive studies were over-represented, and in the few studies that measured later, levels were back to baseline within a few hours.[30] That fits the pulsatile pattern the biology calls for — as a fit, not a demonstration — and it dovetails with the muscle-derived "IL-6 paradox" already described under chronic inflammation and the broader case for resistance training.
What actually helps
Vaccination — Strong (randomised trials). Exercise — Moderate for the short IL-15 rise, Weak for slowing immune aging itself (observational). Energy balance — Weak (rat data). Sleep — Weak (one meta-analysis on vaccine response).
As with every hallmark, the evidence is strongest for the unglamorous interventions. The lifestyle levers below work by keeping the whole body in good metabolic and inflammatory order rather than by targeting IL-15 directly; the one countermeasure with randomised-trial evidence works around the aging immune system instead.
Vaccines that work in older adults. Because the aging immune system responds less to vaccines, higher-dose flu vaccines were developed for people over 65. Across 14 trials in more than half a million older adults, they cut flu hospitalisations by about 40% compared with the standard dose — about 4 fewer per 10,000 people vaccinated — with no clear effect on deaths. The authors call the absolute benefit modest,[31] and the largest single trial missed its broader main goal of fewer flu-or-pneumonia hospitalisations, though flu hospitalisations alone were lower.[32] A newer vaccine against respiratory syncytial virus (RSV) cut RSV hospitalisations in people over 60 by more than 80% in a large, open-label, manufacturer-funded Danish trial, though the numbers were small — 3 versus 18 cases among about 65,000 people in each group.[33] The recombinant shingles vaccine, which contains an immune-boosting ingredient called an adjuvant, prevented about 90% of shingles even in people over 80. That is evidence that a well-designed vaccine can largely work around the aging immune system, at the cost of sore arms and short-lived flu-like reactions in most recipients.[34] Its possible effect on dementia is covered on the shingles vaccine page.
Exercise — the most plausible lifestyle lever, though the human evidence on immune aging itself is thin. Exercise is worth doing for many other reasons; the question here is narrower. In one meta-analysis, a session of either kind — endurance or strength work — was followed by a short rise in blood IL-15, though a larger one found the rise less consistent.[35] Whether harder sessions do more has not been tested, and whether that rise actually sharpens NK or memory T-cells in people is inferred from lab work, not measured.[36] The best human study of immune aging is a snapshot: people aged 55 to 79 who had cycled seriously for most of their adult lives had more fresh T-cells leaving the thymus than inactive people their age (similar to young adults), yet carried just as many worn-out T-cells that have lost CD28, a molecule T-cells need for proper activation.[37] Small, bias-prone studies hint that active people respond somewhat better to one flu-vaccine strain.[38] A 2026 umbrella review rated the certainty of every exercise effect on immune-aging blood markers as very low, and no trial has yet shown that exercise slows immune aging.[39] Within muscle, IL-15 shows the same pulse-versus-plateau pattern: in cultured rat muscle cells and in mice, a brief exposure to muscle-level IL-15 raised glucose uptake and mitochondrial function, while sustained exposure helped only at low concentrations and impaired respiratory-chain assembly at higher ones.[40]
Sensible energy balance — though the direct evidence here is animal. In rats, IL-15 signalling and its receptor become chronically over-expressed in fat tissue over the course of aging, which alongside tumour necrosis factor alpha degrades insulin signalling; lifelong calorie restriction — 40% in that experiment, across 36 animals — prevented the pattern.[41] That is a mechanistic hint, not a human dosing recommendation, and 40% restriction is far beyond anything this site suggests. The framing is the same as in the chronic inflammation article: much of the benefit rides on fat loss and dietary quality, not on any schedule trick. One caveat-laden finding: among 61 amateur runners, those getting under 45% of their energy from carbohydrate had lower IL-15 levels — a single-cohort observation at a fairly ordinary intake, not a licence to carb-load.[42]
Sleep. Adequate, regular sleep is a genuine immune-maintenance input, not a recovery nicety. The most direct human evidence concerns vaccines: in a pooled analysis of studies in healthy adults, people whose sleep was measured objectively and who slept too little in the days around a vaccination made noticeably fewer antibodies. But those studies only included adults aged 18 to 60, the effect was clear in men but not statistically significant in women, and self-reported short sleep (under 6 hours) showed no clear effect.[43] The broader argument, that good sleep preserves the anti-inflammatory feedback immune aging erodes, is the same reasoning laid out for inflammaging, and it remains an inference.
The drug and supplement frontier
Weak, and a Caution. None of this is established for healthy adults, and the supplement end of it rests on single small trials, cell culture and animal work.
A great deal of money is chasing IL-15 pharmacologically, and the results are a useful illustration of why the pulsatile principle matters.
- IL-15 superagonists (N-803, formerly ALT-803) are engineered to deliver a strong, long-lasting IL-15 signal, and in cancer trials they have produced real responses — in a phase 1b trial pairing N-803 with nivolumab in metastatic lung cancer, 6 of 21 patients had a partial tumour response (29%, 95% CI 11–52), though that figure was worked out after the fact rather than as a prespecified endpoint. That trial also recorded no dose-limiting toxicities, and never reached a maximum tolerated dose.[44] It is worth being precise about the safety record, because it is often reported more alarmingly than it reads. In the first-in-human study of this superagonist — 33 patients who had relapsed after a stem-cell transplant — no dose-limiting toxicity was identified, and no patient met criteria for severe cytokine-release or capillary-leak syndrome. What did occur was fever and chills with intravenous dosing, an injection-site rash in almost every patient dosed under the skin, and transient hypertension in 83% at the highest doses; responses were seen in 19% of evaluable patients.[45] The dose-limiting harm belongs to free recombinant IL-15 rather than the superagonist complex. In its first-in-human trial, 18 patients received daily intravenous dosing; severe drops in blood pressure, a fall in platelets and liver-enzyme rises forced a tenfold dose reduction, and the best response achieved was stable disease. Even there the authors record only modest capillary leak, in explicit contrast to high-dose interleukin-2 — the drug whose reputation this one tends to inherit.[46] One superagonist has since become an approved medicine. N-803, sold as Anktiva, was approved in the US in 2024 for high-risk bladder cancer that has not invaded the muscle wall, that includes an early flat form called carcinoma in situ, and that no longer responds to the standard treatment, BCG (a weakened relative of the tuberculosis bacterium, instilled into the bladder). It is given into the bladder alongside BCG, and in the single-arm, company-funded trial behind the approval the cancer cleared in about six in ten patients (62% of 77 in the US Food and Drug Administration's analysis).[47][48] Because it is given into the bladder, its safety record says little about IL-15 given into the bloodstream. These are cancer drugs given to seriously ill patients under close monitoring, not longevity tools; the broader class of unproven anti-aging drugs is covered under geroprotectors.
- Engineered IL-15 cell therapies build the cytokine into the NK cells themselves so its signal stays local. NK cells engineered to make their own IL-15, combined with a cancer-targeting receptor, have already been given to patients in small early-phase trials for B-cell lymphomas and leukaemia: 8 of 11 responded in the first report, and about half of 37 once the same trial was expanded, with no cytokine-release syndrome, nerve toxicity or graft-versus-host disease reported.[49][50] These are early cancer trials in seriously ill patients, and nothing like them has been tried for aging. Newer designs that tether IL-15 to its receptor on the cell surface are still cell-culture work.[51]
- Supplements marketed as "exercise mimetics" — beta-alanine, the plant compound eugenol, and multi-ingredient mitochondrial cocktails — are promoted on the strength of IL-15 or its downstream signalling. The evidence for beta-alanine is a single small trial in 22 young male elite volleyball players (11 per group, 4 weeks), published in a journal not indexed in PubMed; it found higher blood IL-15 and better fitness-test scores than placebo, but measured no immune outcome.[52] Eugenol's case rests on mouse and cultured-muscle-cell work only.[53] And in skin cells from older, sedentary women, a 12-ingredient mix switched on genes downstream of IL-15 but did not raise IL-15 itself; the study was funded by a company that holds an IL-15 patent and part-owns a firm selling a product with the same ingredients, and that company's founder and chief executive is an author.[54] None demonstrates an immune or longevity benefit in a healthy person. Treat them as research, not advice.
- Thymus "regeneration." An often-cited regimen of growth hormone, DHEA (dehydroepiandrosterone, a hormone supplement) and metformin rests on one uncontrolled pilot in 9 men, run by a company that holds a related patent; the thymus looked better on scans in 7 of the 9.[55] Its controlled follow-up passed its expected end date in late 2025 with no results posted.[56] Treat it as unproven.
It is also worth knowing that IL-15 is not benign when dysregulated upward: chronically high local IL-15 is a driver of autoimmune disease, most clearly in celiac disease, where gluten-triggered IL-15 in the gut lining breaks immune tolerance and destroys the intestinal surface.[57] More is emphatically not better.
What this does and doesn't tell you
What it tells you: immune aging is real, measurable, and partly tractable. The thymus's output falls, NK and T-cell surveillance fades, and the immune system's failure to clear senescent cells feeds the same inflammaging that drives age-related disease. Researchers can now measure it: immune-age scores built from blood and a thymic-health score read from routine chest scans are each linked to mortality in large cohorts, but these are research tools, and none can yet tell you whether a change you make is working.[58][59] (Two of the developers of one blood score, iAge, co-founded a company that uses it.) IL-15 is a useful thread through the biology, and the organising principle it suggests — that immune cells are rejuvenated by pulses of signalling but exhausted by continuous elevation — is a plausible explanation of why exercise might help and why IL-15 drugs are used only in cancer, under close monitoring. The best-proven lever is vaccination with vaccines designed for older immune systems; then exercise, sensible energy balance and sleep, whose immune-specific evidence is thinner.
What it doesn't tell you: that any IL-15 drug or supplement is safe or beneficial for a healthy person. No trial has tested raising IL-15 in healthy people; continuous IL-15 wears out NK cells in the lab, high local IL-15 in the gut drives celiac disease, and daily intravenous IL-15 caused severe drops in blood pressure, falling platelets and liver-enzyme rises in cancer patients. The centenarian data showing high IL-15 alongside exceptional longevity is observational, reflecting a whole finely-balanced immune phenotype rather than one molecule you can take. As everywhere in this field, the elegance of the mechanism runs well ahead of the proven interventions, and the proven interventions are the unglamorous ones.
Further reading
- Goyani P, et al. Immunosenescence: Aging and Immune System Decline. Vaccines (Basel) 2024.[60]
- Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res 2014.[61]
- Lee H, et al. IL-15 in T-Cell Responses and Immunopathogenesis. Immune Netw 2024.[62]
- Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett 2010.[63]
- Yang JY, et al. Natural killer cells: gatekeepers of healthy aging in longevity medicine. Inflamm Regen 2026.[64]
- Gergues M, et al. Senescence, NK cells, and cancer: navigating the crossroads of aging and disease. Front Immunol 2025.[65]
- Li Y, et al. IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8+ T cells in vitro. J Immunol 2005.[66]
- Weng J, et al. IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. Oncoimmunology 2016.[67]
- Gangemi S, et al. Age-related modifications in circulating IL-15 levels in humans. Mediators Inflamm 2005.[68]
- Tedone E, et al. Telomere length and telomerase activity in T cells are biomarkers of high-performing centenarians. Aging Cell 2019.[69]
- Zhou L, et al. Centenarians Alleviate Inflammaging by Changing the Ratio and Secretory Phenotypes of T Helper 17 and Regulatory T Cells. Front Pharmacol 2022.[70]
- Pinti M, et al. A Comprehensive Analysis of Cytokine Network in Centenarians. Int J Mol Sci 2023.[71]
- Felices M, et al. Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight 2018.[72]
- Crane JD, et al. Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging. Aging Cell 2015.[73]
- Khalafi M, et al. Interleukin-15 responses to acute and chronic exercise in adults: a systematic review and meta-analysis. Front Immunol 2023.[74]
- Nadeau L, et al. IL-15 improves skeletal muscle oxidative metabolism and glucose uptake in association with increased respiratory chain supercomplex formation and AMPK pathway activation. Biochim Biophys Acta Gen Subj 2019.[75]
- Giovannini S, et al. Effects of aging and life-long moderate calorie restriction on IL-15 signaling in the rat white adipose tissue. Eur Rev Med Pharmacol Sci 2020 — rat, n=36, 40% restriction.[76]
- Sierra APR, et al. Chronic Low or High Nutrient Intake and Myokine Levels. Nutrients 2022.[77]
- Romee R, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 2018 — n=33; no dose-limiting toxicity, no capillary-leak syndrome.[78]
- Conlon KC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2015 — n=18; the trial where dose-limiting toxicity was observed.[79]
- Wrangle JM, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 2018 — n=21; no dose-limiting toxicity.[80]
- Waldmann TA, Miljkovic MD, Conlon KC. Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. J Exp Med 2020.[81]
- Steinmann GG, Klaus B, Müller-Hermelink HK. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand J Immunol 1985.[82]
- Douek DC, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998.[83]
- Bernatz S, et al. Thymic health consequences in adults. Nature 2026.[84]
- Kooshesh KA, et al. Health Consequences of Thymus Removal in Adults. N Engl J Med 2023.[85]
- Imai K, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000.[86]
- Ogata K, et al. Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 2001.[87]
- Ovadya Y, et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat Commun 2018.[88]
- Chulenbayeva L, et al. The Trajectory of Successful Aging: Insights from Metagenome and Cytokine Profiling. Gerontology 2024.[89]
- Prado GHJD, et al. The effects of ageing, BMI and physical activity on blood IL-15 levels: A systematic review and meta-analyses. Exp Gerontol 2022.[90]
- Bettariga F, et al. Exercise training mode effects on myokine expression in healthy adults: A systematic review with meta-analysis. J Sport Health Sci 2024.[91]
- Duggal NA, et al. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging Cell 2018.[92]
- Bohn-Goldbaum E, et al. Physical activity and acute exercise benefit influenza vaccination response: A systematic review with individual participant data meta-analysis. PLoS One 2022.[93]
- Chai G, Xue J, Xie B. Effects of exercise and physical activity on circulating inflammaging- and immunosenescence-related biomarkers in older adults and adults with chronic diseases: an umbrella review. Front Immunol 2026.[94]
- Zhao W, et al. Effect of high-dose versus standard-dose influenza vaccines on hospitalisation outcomes and mortality in older adults: a systematic review and meta-analysis. Lancet Healthy Longev 2026.[95]
- Johansen ND, et al. High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults. N Engl J Med 2025.[96]
- Lassen MCH, et al. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. N Engl J Med 2026.[97]
- Cunningham AL, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016.[98]
- Spiegel K, et al. A meta-analysis of the associations between insufficient sleep duration and antibody response to vaccination. Curr Biol 2023.[99]
- Chamie K, et al. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. NEJM Evid 2023.[100]
- Liu E, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 2020.[101]
- Marin D, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1/2 trial. Nat Med 2024.[102]
- Huang T, et al. Eugenol mimics exercise to promote skeletal muscle fiber remodeling and myokine IL-15 expression by activating TRPV1 channel. Elife 2024.[103]
- Fahy GM, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell 2019.[104]
- Alpert A, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med 2019.[105]
- Sayed N, et al. An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging. Nat Aging 2021.[106]